Skip to content

Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis

Expert Patient Self-management Programme Versus Usual Care in Bronchiectasis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01117493
Enrollment
64
Registered
2010-05-05
Start date
2006-09-30
Completion date
2007-10-31
Last updated
2010-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchiectasis

Brief summary

The aim of this exploratory randomized controlled trial was to investigate the efficacy of a disease specific Expert Patient Programme compared to usual care in patients with bronchiectasis. Hypothesis: Disease specific EPP will increase self efficacy compared to usual care.

Interventions

BEHAVIORALExpert Patient Programme

Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.

BEHAVIORALUsual care

Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.

Sponsors

University of Ulster
CollaboratorOTHER
Belfast Health and Social Care Trust
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (\>18 years) with a primary diagnosis of bronchiectasis based on a respiratory physician's assessment including a computed tomography scan were included in the study

Exclusion criteria

* Primary diagnosis of cystic fibrosis * Patients with methicillin-resistant Staphylococcus aureus infection * Patients with any condition that would have an impact on the assessment procedures (e.g. sensory impairment, pregnancy, language barriers) * Any factor that would prevent adherence to the self-management programme.

Design outcomes

Primary

MeasureTime frameDescription
Self-efficacy8 monthsSelf efficacy is measured using the Chronic Disease Self Efficacy Scale. Confidence is measured on a 1-10 point Likert scale for 10 subscales. There are no specific units for this measurement.

Secondary

MeasureTime frameDescription
Perception of illness8 monthsPerception of illness is measured using the Illness Perception Questionnaire - revised IPQ-R. This questionnaire has 8 domains. Minimum score 52 and maximum 204. There are no specific units for this measurement.
Health related quality of life8 monthsHealth related quality of life is measured using the St Georges Respiratory Questionnaire. This questionnaire has 3 domains. Min-max scores 0-100%
Self rated health8 monthsAn expert patient programme questionnaire is used to record self rated health, management of condition, days lost to work and social activities, satisfaction and benefits. There are no specific units for this measurement.
Lung function8 monthsSpirometric measurement of FEV1 expressed as a percentage predicted is used to assess lung function
Rate of exacerbation8 monthsFrequency of antibiotics is recorded to assess rate of exacerbation. These will be expressed as the number of antibiotics prescribed per group during the study.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026